The addition of the recently approved resmetirom or the understudy lanifibranor, obeticholic acid, aramchol, etc. is not likely to affect the position gradually established by SGLT2-is and GLP-1RAs in the treatment of patients with MASLD. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.